Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Economic burden and healthcare resource utilization

13 evidence topics · 13 sources

Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018

“In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, costs for patients with advanced fibrosis were higher (€3,983) than for those with early-stage fibrosis (€2,224).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A major share of indirect costs resulted from early retirement or stopping working (74%), followed by time off work in the previous 12 months (26%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patient indirect or productivity-related costs correlated positively with NASH severity, because patients with relatively more severe disease had to stop working (12% vs. 5% in patients with early-stage disease) or cited that their retirement was the result of NASH (13% vs. 5% in patients with early-stage disease)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Annual direct medical cost by liver health state, 2025 US dollars, payer-perspective model funded by a diagnostics manufacturer
All-cause annual costs by FIB-4 category in 6,743 US adults with NASH, linked electronic health record and claims data, 2016 to 2020
Health care resource use and work impairment in 136 US adults with NASH versus matched general population, 2016 National Health and Wellness Survey

“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In terms of HRU, there were more visits to an HCP (8.43 vs. 5.17, p < 0.001), ER visits (0.73 vs. 0.38, p = 0.021), and hospitalizations (0.43 vs. 0.21, p = 0.024) for NASH compared to the matched general population cohort (Fig. 3) and NASH patients reported more specialty visits (p’s < 0.05), for example, more general/family medicine provider visits (1.49 vs. 1.14, p = 0.040), hepatologist visits (0.10 vs. 0.02, p = 0.022), and gastroenterologist visits (0.38 vs. 0.12 p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Impairment of work and activity on WPAI was significantly higher for NASH patients compared to matched general population cohort, including absenteeism (17.0% vs. 9.2%, p = 0.041) and presenteeism (32.9% vs. 22.2%, p = 0.019), as well as overall work impairment (39.6% vs. 26.2%, p = 0.011), and activity impairment (44.7% vs. 30.8%, p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Work productivity and activity impairment by fibrosis risk category in 429 US adults with MASH, 2019 and 2022 physician and patient surveys